Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Blood Neoplasia|January 15, 2026
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemiaTapan M Kadia, Akhil Jain, Caitlin R Rausch, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Leukemia & Lymphoma|April 8, 2021
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemiaLydia L Benitez, Anthony J Perissinotti, Caitlin R Rausch, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
American Journal of Hematology|March 26, 2025
Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes From the HERO ConsortiumLydia L Benitez, Kayleigh R Marx, Caitlin R Rausch, et al.
Leukemia & Lymphoma|August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemiaHussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
Acta Haematologica|May 12, 2020
Treating Leukemia in the Time of COVID-19Shilpa Paul, Caitlin R Rausch, Nitin Jain, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
Pageof 4